Announcement Overview
Piramal Pharma Solutions (PPS), a global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd (PPL) (NSE: PPLPHARMA, BSE: 543635), announced the addition of a 4.3 MWp ground‑mounted solar power plant at its integrated drug substance and drug product facility in Morpeth, United Kingdom. The installation, covering approximately 16 acres, will comprise around 6,200 solar panels and is expected to generate roughly 3,950 MWh of renewable electricity each year.
Operational Impact
The solar output is projected to meet about 22% of the Morpeth site’s annual electricity demand and is sufficient to power an estimated 1,460 UK homes. Over a 25‑year horizon, the plant will avoid the emission of approximately 20,000 tCO₂e, contributing directly to PPL’s broader decarbonisation target of reducing Scope 1 and Scope 2 greenhouse‑gas emissions by 42% by fiscal year 2030.
Commercial Arrangement and Timeline
The project is being delivered under a Power Purchase Agreement (PPA) with Alight UK BTM1 Limited, a leading solar developer and independent power producer. Operational commencement is scheduled for the first quarter of 2027, providing the site with a sustainable, cost‑effective source of onsite electricity and enhancing energy‑supply resilience.
Executive Commentary
Frank Bugg, Senior Vice President, UK & Europe Operations and Managing Director of Piramal Pharma Solutions, stated that the company integrates sustainability principles across its global network and that the partnership with Alight adds value for customers and shareholders. Rob Stait, Managing Director, Behind the Meter at Alight, highlighted that UK businesses are seeking practical ways to lower emissions, strengthen energy resilience, and manage long‑term energy costs, and that the Morpeth project demonstrates how onsite solar can deliver all three objectives.
Corporate Context
PPS offers end‑to‑end development and manufacturing services across the drug lifecycle, including APIs, finished dosage forms, highly potent APIs, antibody‑drug conjugates, sterile fill/finish, peptide products, and biologics such as vaccines and gene therapies through its subsidiary Yapan Bio Private Limited. Piramal Pharma Ltd operates 17 global development and manufacturing facilities, a distribution network in over 100 countries, and includes businesses such as Piramal Critical Care and Piramal Consumer Healthcare. An associate company, Abbvie Therapeutics India Private Limited—a joint venture between Abbvie and PPL—has become a market leader in ophthalmology therapies in India.